Protalix BioTherapeutics Reports 2017 First Quarter Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Protalix BioTherapeutics (PLX) Reports Q1 Loss of $0.48/Shre
May 10, 2017 8:47 AM EDTProtalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of ($0.48), versus ($0.09) reported last year. Revenue for the quarter came in at $2.9 million versus the consensus estimate of $679 thousand.
Positive Results from Phase II Trial in CF Program with Number of Potential Strategic Alternatives for... More